MS Treatment Extends Time to Symptoms

Este contenido no está disponible en español en este momento. Nos dedicamos a traducir más contenido de nuestro sitio web. Si usa un complemento de explorador para traducir el contenido en inglés al español, por favor, tome en cuenta que la traducción quizá no sea exacta.

15 de diciembre de 2022

teriflunomide (Aubagio®, Genzyme Sanofi) that is ongoing outside of the U.S. and no longer recruiting

A trial of ocrelizumab (Ocrevus®, Genentech) that is recruiting 100 people at sites in the U.S. — site information is available on the study’s clinicaltrials.gov page

A trial testing a tuberculosis vaccine that is recruiting in Italy

“Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome‚” by Drs. Darin T. Okuda, Orhun Kantarci, Christine Lebrun-Frénay, Maria Pia Sormani, Christina J. Azevedo, Francesca Bovis, Le H. Hua, Lilyana Amezcua, Ellen M. Mowry, Christophe Hotermans, Jason Mendoza, John S. Walsh, Christian von Hehn, Wendy S. Vargas, Stacy Donlon, Robert T. Naismith, Annette Okai, Gabriel Pardo, Pavle Repovic, Olaf Stüve, Aksel Siva, and Daniel Pelletier, is published in Annals of Neurology (published online November 18, 2022)." c-nmssatomrichtext_nmssatomrichtext-host="">

The first results from attempts to prevent or slow the development of multiple sclerosis have been published. In a clinical trial, dimethyl fumarate (Tecfidera®, Biogen) extended the time before the development of a first neurological symptom significantly more than placebo. Participants had a rare condition called radiologically isolated syndrome, with MS-like brain lesions on MRI but no detectable symptoms. This first completed trial of its kind adds to the idea that early treatment is protective against disease activity. Additional trials, now underway, should help determine who among those with RIS may benefit from early treatment.

Background: Although not considered a course of MS, radiologically isolated syndrome (RIS) is a rare condition involving people who show lesions on MRI of the brain and/or spinal cord that are consistent with those found in MS and who have no detectable neurological symptoms or abnormalities. Previous research suggests that about half of those classified as having RIS are likely to develop definite MS within ten years.
The Study: Dr. Darin Okuda (University of Texas Southwestern Medical Center) led a team from 12 MS centers who recruited 87 people with RIS and randomly assigned them either to oral dimethyl fumarate (240 mg twice daily) or to inactive placebo for 96 weeks. The primary goal of the study was to determine whether treatment would extend the time it took for participants to develop a first neurological symptom. The team also assessed disease activity on MRI scans.
Fourteen people in each group did not complete the study, in part because the study was terminated early due to low trial enrollment.
Results: Significantly fewer participants who received dimethyl fumarate experienced a neurological symptom compared to those on placebo. Treatment also significantly reduced the occurrence of MRI-detected disease activity.
Moderate adverse effects were more common in people taking dimethyl fumarate and included mostly infections and muscle pain/weakness.
Impact: This first completed trial of its kind adds to the idea that early treatment is protective and supports the idea that MS can begin well before symptoms emerge. Further study is needed, in larger numbers of people with RIS. Additional trials are underway, including:
- A trial of teriflunomide (Aubagio®, Genzyme Sanofi) that is ongoing outside of the U.S. and no longer recruiting
- A trial of ocrelizumab (Ocrevus®, Genentech) that is recruiting 100 people at sites in the U.S. — site information is available on the study’s clinicaltrials.gov page
- A trial testing a tuberculosis vaccine that is recruiting in Italy

teriflunomide (Aubagio®, Genzyme Sanofi) that is ongoing outside of the U.S. and no longer recruiting

A trial of ocrelizumab (Ocrevus®, Genentech) that is recruiting 100 people at sites in the U.S. — site information is available on the study’s clinicaltrials.gov page

A trial testing a tuberculosis vaccine that is recruiting in Italy

Background: Although not considered a course of MS, radiologically isolated syndrome (RIS) is a rare condition involving people who show lesions on MRI of the brain and/or spinal cord that are consistent with those found in MS and who have no detectable neurological symptoms or abnormalities. Previous research suggests that about half of those classified as having RIS are likely to develop definite MS within ten years.
The Study: Dr. Darin Okuda (University of Texas Southwestern Medical Center) led a team from 12 MS centers who recruited 87 people with RIS and randomly assigned them either to oral dimethyl fumarate (240 mg twice daily) or to inactive placebo for 96 weeks. The primary goal of the study was to determine whether treatment would extend the time it took for participants to develop a first neurological symptom. The team also assessed disease activity on MRI scans.
Fourteen people in each group did not complete the study, in part because the study was terminated early due to low trial enrollment.
Results: Significantly fewer participants who received dimethyl fumarate experienced a neurological symptom compared to those on placebo. Treatment also significantly reduced the occurrence of MRI-detected disease activity.
Moderate adverse effects were more common in people taking dimethyl fumarate and included mostly infections and muscle pain/weakness.
Impact: This first completed trial of its kind adds to the idea that early treatment is protective and supports the idea that MS can begin well before symptoms emerge. Further study is needed, in larger numbers of people with RIS. Additional trials are underway, including:
- A trial of teriflunomide (Aubagio®, Genzyme Sanofi) that is ongoing outside of the U.S. and no longer recruiting
- A trial of ocrelizumab (Ocrevus®, Genentech) that is recruiting 100 people at sites in the U.S. — site information is available on the study’s clinicaltrials.gov page
- A trial testing a tuberculosis vaccine that is recruiting in Italy

nationalmssociety.org, Facebook, X, anteriormente conocida como Twitter, Instagram, YouTube o 1-800-344-4867." c-nmssatomrichtext_nmssatomrichtext-host="">

Acerca de la esclerosis múltiple

La esclerosis múltiple es una enfermedad impredecible del sistema nervioso central. En la actualidad no hay cura. Los síntomas varían de una persona a otra y pueden incluir fatiga discapacitante, dificultad de movimiento, cambios cognitivos y problemas de visión. Se calcula que 1 millón de personas en Estados Unidos tienen esclerosis múltiple. El diagnóstico y el tratamiento oportunos son cruciales para minimizar la discapacidad. Se logran avances considerables hacia un mundo libre de esclerosis múltiple.

Acerca de la Sociedad Nacional de Esclerosis Múltiple

La Sociedad Nacional de Esclerosis Múltiple, fundada en 1946, es el líder mundial de un movimiento cada vez mayor para librar al mundo de la esclerosis múltiple. La Sociedad financia investigación de vanguardia para una cura, impulsa cambios con activismo y ofrece programas y servicios para ayudar a las personas afectadas por la esclerosis múltiple a vivir con ella de mejor manera. Conéctese para obtener más información y participar: nationalmssociety.org, Facebook, X, anteriormente conocida como Twitter, Instagram, YouTube o 1-800-344-4867.

nationalmssociety.org, Facebook, X, anteriormente conocida como Twitter, Instagram, YouTube o 1-800-344-4867." c-nmssatomrichtext_nmssatomrichtext-host="">

MS Treatment Extends Time to First Symptom in Trial in People With Radiologically Isolated Syndrome (RIS)